A multidisciplinary research team at Aarhus University has provided fundamental new insight into the mechanism of the medical drug dimethyl fumarate, which is the active component of important treatments for multiple sclerosis ...
Nov 1, 2018
0
3
An antiviral medication which effectively inhibits replication of the coronavirus causing the COVID-19 and, at the same time, fights the immune reaction that is killing COVID-19 patients around the world.
Oct 2, 2020
0
31
Understanding and mitigating the role of epigenetics (environmental influences that trigger changes in gene expression) in disease development is a major goal of researchers. Now, a newly published paper featured on the March ...
Feb 28, 2019
0
4
(HealthDay)—An active ingredient in some psoriasis and multiple sclerosis medications, dimethyl fumarate, has been linked to two cases of progressive multifocal leukoencephalopathy (PML), according to two letters published ...
Apr 9, 2015
0
7
A medication used to treat multiple sclerosis (MS) also has a beneficial effect on the composition of the intestinal flora, according to researchers from the University of Basel and the University Hospital Basel. Conversely, ...
Dec 1, 2022
0
25
In 2014, the European Medicines Agency approved the drug Tecfidera for the treatment of relapsing multiple sclerosis, a neurodegenerative disease that affects millions of people worldwide. In multiple sclerosis, inflammation ...
Sep 30, 2021
0
14
A multidisciplinary team at the University of Alberta is seeking to understand how monkeypox (mpox) virus may be causing neurological symptoms in people affected by the global outbreak of mpox disease, declared by the World ...
Feb 16, 2024
0
10
(HealthDay)—Rituximab has better efficacy and lower discontinuation rates than other disease-modifying treatment (DMT) choices for newly diagnosed relapsing-remitting multiple sclerosis (RRMS), according to a study published ...
Jan 9, 2018
0
3
Dimethyl fumarate (trade name: Tecfidera) has been approved since January 2014 for adults with relapsing remitting multiple sclerosis (RRMS). In an early benefit assessment pursuant to the Act on the Reform of the Market ...
Aug 7, 2014
0
0
More patients with pediatric-onset multiple sclerosis (POMS) are free of new or newly enlarging (N or NE) T2 hyperintense lesions with dimethyl fumarate (DMF) versus interferon β-1a (IFNβ-1a) treatment, and the annualized ...
Oct 6, 2022
0
45
